A prospective study slated for publication has demonstrated that Precision Therapeutics' ChemoFx test was able to predict whether ovarian cancer patients would live longer if they took a particular chemotherapy.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.